VRDN
Viridian Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Viridian Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
+6.83%
vs ±17.2% implied · ×0.40
shaded = implied · ▲▼ = realized
Fund move
Fund move
Viridian Therapeutics, Inc.
24.69
−0.11 · −0.44%
post 24.69 −0.01%
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | FMRFMR | $305.0M | 12.15% | +7.97% | |
| 2 | BlackRockBlackRockindex-like | $157.1M | 6.26% | +9.19% | |
| 3 | Bellevue GroupBellevue | $123.7M | 4.93% | +0.09% | |
| 4 | Paradigm Biocapital AdvisorsParadigm Biocapital | $123.5M | 4.92% | +113.53% | |
| 5 | Kynam Capital ManagementKynam | $118.6M | 4.72% | +175.61% | |
| 6 | State StreetState Streetindex-like | $112.5M | 4.48% | +31.07% | |
| 7 | T. Rowe Price AssociatesT. Rowe Price | $105.6M | 4.21% | +79.30% | |
| 8 | Fairmount Funds ManagementFairmount Funds | $93.5M | 3.73% | +30.05% | |
| 9 | Vanguard Capital ManagementVanguardindex-like | $84.1M | 3.35% | +9.83% | |
| 10 | Deep Track CapitalDeep Track Capital | $66.0M | 2.63% | +157.74% | |
| 11 | VR AdviserVR Adviser | $59.8M | 2.38% | −16.09% | |
| 12 | Wellington Management GroupWellington | $57.5M | 2.29% | +1.62% | |
| 13 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $50.6M | 2.01% | +67.70% | |
| 14 | Geode Capital ManagementGeodeindex-like | $46.0M | 1.83% | +7.23% | |
| 15 | venBio Select AdvisorvenBio Select Advisor | $45.9M | 1.83% | +66.67% | |
| 16 | Baker Bros. AdvisorsBaker Bros. | $43.8M | 1.74% | +20.86% | |
| 17 | Point72 Asset ManagementPoint72 | $43.3M | 1.72% | +629.85% | |
| 18 | Caligan PartnersCaligan Partners | $40.3M | 1.61% | new | |
| 19 | NovoNovo | $39.2M | 1.56% | +6.75% | |
| 20 | Tang Capital ManagementTang | $32.9M | 1.31% | 0.00% | |
| 21 | Fisher Asset ManagementFisher | $32.2M | 1.28% | −0.99% | |
| 22 | Candriam Luxembourg S.C.A.Candriam Luxembourg S.C.A. | $31.3M | 1.25% | +139.93% | |
| 23 | Goldman Sachs GroupGoldman Sachs | $31.1M | 1.24% | +6.24% | |
| 24 | First Turn ManagementFirst Turn | $30.7M | 1.22% | +83.25% | |
| 25 | Dimensional Fund AdvisorsDimensional | $29.6M | 1.18% | +204.20% |
217 managers report $2.5B of Viridian Therapeutics on form 13F for the quarter ended Jun 30 '26. 30 of them hold 80% of it; FMR is largest at 12.15%.
Expected move
Inputs8Q avg ±9.3%·×1.14·fair
straddle ±15.1%
spot 24.67exp Nov 20ATM strike 25ATM straddle 4.38IV 91%